Amarin Corp PLC ADR AMRN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AMRN is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.86
- Day Range
- $0.83–0.87
- 52-Week Range
- $0.65–2.23
- Bid/Ask
- $0.84 / $0.85
- Market Cap
- $349.74 Mil
- Volume/Avg
- 1,289 / 1.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- 15.37
- Price/Sales
- 1.08
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its lead product includes Vascepa.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- —
- Total Number of Employees
- 365
- Website
- https://amarincorp.com
Valuation
|
Metric
|
AMRN
|
|---|---|
Price/Earnings (Normalized) | 15.37 |
Price/Book Value | 0.63 |
Price/Sales | 1.08 |
Price/Cash Flow | — |
Price/Earnings
AMRN
Financial Strength
|
Metric
|
AMRN
|
|---|---|
Quick Ratio | 1.66 |
Current Ratio | 2.69 |
Interest Coverage | — |
Quick Ratio
AMRN
Profitability
|
Metric
|
AMRN
|
|---|---|
Return on Assets (Normalized) | 2.55% |
Return on Equity (Normalized) | 3.85% |
Return on Invested Capital (Normalized) | 2.24% |
Return on Assets
AMRN
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
LLY
| Eli Lilly and Co | Gyg | $567.7 Bil | |
JNJ
| Johnson & Johnson | Ftxh | $371.7 Bil | |
ABBV
| AbbVie Inc | Fttnnl | $263.6 Bil | |
MRK
| Merck & Co Inc | Lzq | $262.9 Bil | |
RHHBY
| Roche Holding AG ADR | Pbqh | $233.3 Bil | |
NVS
| Novartis AG ADR | Clt | $198.9 Bil | |
AZN
| AstraZeneca PLC ADR | Tvxnl | $197.5 Bil | |
PFE
| Pfizer Inc | Frt | $162.5 Bil | |
AMGN
| Amgen Inc | Fyh | $144.0 Bil | |
SNY
| Sanofi SA ADR | Snlq | $116.5 Bil |